| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1099-0496(200007)30:1<10::AID-PPUL3>3.0.CO;2-Q |
| P698 | PubMed publication ID | 10862157 |
| P2093 | author name string | J Mortensen | |
| D V Schidlow | |||
| I Talmaciu | |||
| L Varlotta | |||
| P2860 | cites work | Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis | Q35627382 |
| Xanthomonas maltophilia: an emerging nosocomial pathogen | Q38714858 | ||
| Pseudomonas colonization in cystic fibrosis. A study of 160 patients | Q39602024 | ||
| Pseudomonas cepacia infection in cystic fibrosis: an emerging problem | Q40829590 | ||
| Treatment of pulmonary infections in patients with cystic fibrosis: A comparative study of ticarcillin and gentamicin | Q41221196 | ||
| Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients | Q44063120 | ||
| Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome | Q44445035 | ||
| Microbiology of sputum from patients at cystic fibrosis centers in the United States | Q44982403 | ||
| Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. | Q54127739 | ||
| Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population. | Q54200267 | ||
| Moxalactam-tobramycin-resistant Pseudomonas aeruginosa Isolates in Patients with Cystic Fibrosis | Q54492446 | ||
| Perspectives in Cystic Fibrosis | Q66947766 | ||
| Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients | Q70071088 | ||
| Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis | Q70363287 | ||
| Stenotrophomonas maltophilia in cystic fibrosis patients | Q70911041 | ||
| Cystic fibrosis | Q71767385 | ||
| Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence | Q74683395 | ||
| Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period | Q77181226 | ||
| P433 | issue | 1 | |
| P921 | main subject | Stenotrophomonas maltophilia | Q142705 |
| cystic fibrosis | Q178194 | ||
| P304 | page(s) | 10-15 | |
| P577 | publication date | 2000-07-01 | |
| P1433 | published in | Pediatric Pulmonology | Q15749800 |
| P1476 | title | Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis | |
| P478 | volume | 30 |
| Q24197517 | Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis |
| Q24197766 | Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis |
| Q24235754 | Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis |
| Q90441476 | Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis |
| Q26471114 | Antibiotic treatment forStenotrophomonas maltophiliain people with cystic fibrosis |
| Q44276973 | Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with noncystic fibrosis isolates |
| Q36749895 | Antimicrobial therapy for Stenotrophomonas maltophilia infections |
| Q35536357 | Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. |
| Q37812469 | Challenging and emerging pathogens in cystic fibrosis |
| Q34491552 | Clinical significance of microbial infection and adaptation in cystic fibrosis |
| Q40507596 | Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients |
| Q35226211 | Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies |
| Q81898474 | Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients |
| Q92493935 | Epidemiological Trends and Resistance Associated with Stenotrophomonas maltophilia Bacteremia: A 10-Year Retrospective Cohort Study in a Tertiary-Care Hospital in Hungary |
| Q57913664 | Identification and management of unusual pathogens in cystic fibrosis |
| Q47899379 | Identification of genomic groups in the genus Stenotrophomonas using gyrB RFLP analysis |
| Q24672751 | Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia |
| Q35545544 | Infection control in cystic fibrosis |
| Q90003656 | Longitudinal survey of microbiome associated with particulate matter in a megacity |
| Q34956792 | Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients |
| Q77222812 | Management of an older patient with Stenotrophomonas maltophilia: is it an emerging pathogen in cystic fibrosis? |
| Q44999792 | Management of pulmonary involvement in mucoviscidosis in the child |
| Q92324719 | Microbiology of Cystic Fibrosis Airway Disease |
| Q33877139 | Role of excessive inflammatory response to Stenotrophomonas maltophilia lung infection in DBA/2 mice and implications for cystic fibrosis |
| Q37637169 | Sputum DNA sequencing in cystic fibrosis: non-invasive access to the lung microbiome and to pathogen details. |
| Q47126542 | Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy |
| Q47190939 | Stenotrophomonas maltophilia: A marker of lung disease severity |
| Q37763019 | Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review |
| Q33825634 | The changing microbial epidemiology in cystic fibrosis |
| Q79363107 | [Antibiotic therapy against Pseudomonas aeruginosa and other gram-negative bacteria in cystic fibrosis] |
| Q53960642 | [Multiresistant pathogens in cystic fibrosis] |
Search more.